<DOC>
	<DOCNO>NCT01775449</DOCNO>
	<brief_summary>Use lay language . Oxaliplatin reference anticancer drug treatment colorectal cancer . However , use hamper specific neurotoxicity , characterize acute thermal hypersensitivity , notably cold temperature , chronic neuropathy appear repetition chemotherapy cycle . To date effective therapy able prevent and/or treat adverse drug reaction . So oncologists sometimes strained decrease anticancer dose stop chemotherapy ; Previously , polyamine deficient diet able prevent acute oxaliplatin-induced hypersensitivity animal . So hypothesizes specific nutritional therapy , polyamine deprive diet , may prevent acute oxaliplatin-induced hypersensitivity patient .</brief_summary>
	<brief_title>Prevention Oxaliplatin-induced Neuropathic Pain Specific Diet</brief_title>
	<detailed_description>This prospective , single-center , control interventional study two parallel group randomize single-blind . After obtain informed consent , include patient randomize , either : - group polyamines deplete diet : 2-4 can per day Polydol® ( oral alimentation without polyamines ) , associate predefined menu low polyamines , accord chemotherapy cycle 107 day - control group normal polyamines contain diet : 1 per day Polydol® associate predefined menu normal average polyamines 107 day . Randomization perform consider stratification tumor presence , one polyamines source ( Linsalata Russo , 2008 ) could influence result study . In addition , patient compliance collect case report form along study , include statistical analysis study .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients affect gastrointestinal cancer , without cytotoxic neurotoxic chemotherapy , receive FOLFOX 4 chemotherapy ( folinic acid + 5FU + oxaliplatin ) adjuvant , neoadjuvant palliative situation expect period 8 cure treatment 4 month . Patients give write , free inform consent Patient 's member social security scheme Patients participate another clinical trial within 15 day baseline ( possibility participate / participate observational trial ) Effective contraception patient , male female , childbearing age . Neutrophils &gt; 2.109/L and/or platelet &gt; 100.109/L first treatment cycle Patient receive FOLFOX 4 whatever reason Patients &lt; 18 year old &gt; 70 year old Malnourished patient ( French National Authority Health , 2003 ) Patients part upper limb amputation Diabetic patient Patients neuropathy Oral nutrition impossible Painful procedure schedule baseline ( e.g . surgical excision ) Neurological disorder ( e.g . parkinsonism , stroke ... ) Alcohol consumption upper 3 alcohol unit ( 30 g ) men upper 2 alcohol unit ( 20 g ) woman Patients already receive cytotoxic neurotoxic chemotherapy ( taxanes , platinum salt vinca alkaloid ) Patients treat another cancer within 5 year except basal cell skin carcinoma situ cervical cancer Any unbalance progressive disease ( hepatic failure , renal insufficiency ( creatinine clearance &lt; 30 mL / min ) , respiratory failure , congestive heart failure , myocardial infarction within past 6 month ... ) Patients require Ca2 + Mg2 + perfusion Hypersensitivity allergy know one study product 's component Pregnant woman breastfeed woman Legal disability ( person deprive liberty guardianship ) Patients psychological , social , family geographical reason monitor regularly / compliant requirement study Patients already include another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Anticancer drug ;</keyword>
	<keyword>Oxaliplatin ;</keyword>
	<keyword>Digestive cancer system</keyword>
	<keyword>Acute oxaliplatin-induced hypersensitivity</keyword>
	<keyword>Hyperalgesia ;</keyword>
	<keyword>Allodynia ;</keyword>
	<keyword>Dysesthesia</keyword>
	<keyword>Polyamines deplete diet</keyword>
</DOC>